A new trading day began on Tuesday, with Ginkgo Bioworks Holdings Inc (NYSE: DNA) stock price down -6.76% from the previous day of trading, before settling in for the closing price of $9.17. DNA’s price has ranged from $5.00 to $18.55 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 31.19% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 46.09%. With a float of $37.41 million, this company’s outstanding shares have now reached $43.08 million.
In an organization with 834 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 73.59%, operating margin of -198.27%, and the pretax margin is -199.02%.
Ginkgo Bioworks Holdings Inc (DNA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ginkgo Bioworks Holdings Inc is 32.63%, while institutional ownership is 57.97%. The most recent insider transaction that took place on Jun 17 ’25, was worth 897. Before that another transaction happened on Jun 16 ’25, when Company’s Officer proposed sale 99 for $9.04, making the entire transaction worth $895.
Ginkgo Bioworks Holdings Inc (DNA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 46.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 57.48% during the next five years compared to -27.97% drop over the previous five years of trading.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Here are Ginkgo Bioworks Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.88. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.99, a number that is poised to hit -1.46 in the next quarter and is forecasted to reach -4.05 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.31 million. That was inferior than the volume of 1.46 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 60.90%. Additionally, its Average True Range was 0.65.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 29.96%, which indicates a significant decrease from 52.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.00% in the past 14 days, which was lower than the 104.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.66, while its 200-day Moving Average is $8.59. However, in the short run, Ginkgo Bioworks Holdings Inc’s stock first resistance to watch stands at $8.90. Second resistance stands at $9.24. The third major resistance level sits at $9.42. If the price goes on to break the first support level at $8.38, it is likely to go to the next support level at $8.20. Assuming the price breaks the second support level, the third support level stands at $7.86.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
With a market capitalization of 500.45 million, the company has a total of 58,532K Shares Outstanding. Currently, annual sales are 227,040 K while annual income is -547,030 K. The company’s previous quarter sales were 48,320 K while its latest quarter income was -90,960 K.
